The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. - Wikidata - wikimedia - TriplyDB

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

http://www.wikidata.org/entity/Q34655437

about

Combination versus sequential single agent chemotherapy for metastatic breast cancer Combination versus sequential single agent chemotherapy for metastatic breast cancer Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis Presentation and management of docetaxel-related adverse effects in patients with breast cancer Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer.A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation.Monitoring the progression of metastatic breast cancer on nanoporous silica chips.Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers Tumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer The effect of care setting in the delivery of high-value colon cancer care Predicting survival of de novo metastatic breast cancer in Asian women: systematic review and validation study.Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.Retrospective analysis of metastatic behaviour of breast cancer subtypes Defining the survival benchmark for breast cancer patients with systemic relapse Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

P2860

Q24201726-F7263A15-8623-4BE5-95FF-25DEFFDE39C0 Q24234874-06E59D5E-5905-4682-A712-AA8334AFE492 Q26745420-A79AED94-C906-4275-A720-D64C1168C02D Q26749476-957A464F-1462-4333-B3FB-C776C7FE93B9 Q30992939-FACA3DDE-466C-407A-97D1-2CAA4D128E89 Q31006508-E6304F5B-A66E-41D9-BFAF-54E8D2B14EF3 Q33408664-4914AF6E-3594-43B6-8A20-0CC1113E0501 Q33424566-46D7DB25-522A-4333-A8D1-8EEF5DF51890 Q33518321-3339D0B1-2FA1-4EC5-88D9-7D174C5EFCD4 Q33599906-EDECCB83-5957-4567-BCA9-ABB307A61373 Q33698286-04BF8EA3-B004-42C1-9C78-3CC8040D8E01 Q33703527-ABC1C6FD-FCB7-49C9-83AF-439F6D1F8A1B Q33715354-6F7B450D-61F1-4E0C-A8E7-5196FC288CB9 Q33858930-C43E0B13-40BD-47FC-B87D-F276780531BC Q33872793-AB4F4B49-03E0-4B42-B304-D4D03032CEAD Q33913545-B7CA2B56-506F-4236-8AC3-BCC98D3ACB77 Q33966430-AE0125A2-6E3B-4624-9A5B-CC97394651A7 Q34033757-9A3C1D86-031B-41BF-BB61-2599F22DF0B5 Q34122784-91F16F8D-1104-48C9-B4C3-E663EB7834AE Q34130479-900AE7BC-CEA5-48F6-A5DC-0A760D1EED83 Q34213855-263869F2-6B65-48E9-8658-A9FC4BE98636 Q34217019-497508DC-420C-4153-B13B-8C5ADBAF8CBD Q34234831-B9B56EBC-9482-4BAF-82AF-CDF40E0C78E8 Q34253243-7A62DDBE-5F70-4865-8740-0FDB1248A69C Q34402487-0CE9F530-7A3A-4FCC-9A89-965AA9B35C2F Q34803360-47AAEDBD-5F7D-49A2-B7CC-A4E395EBBA0E Q34870267-DC06A975-4C1D-45C3-AC51-5808DCC43762 Q34983601-BCAC37B6-5690-4089-9B25-7E20124557E3 Q34997475-18E323AA-8D38-44ED-B436-ACE17FBCDB83 Q35077470-BE21133A-04D3-4550-9A64-D80E4F22F611 Q35138699-E4869C77-81E2-4C76-A993-C4A39F369672 Q35164247-BE7E04C6-A00E-4B4C-8057-BDE2BE38C99B Q35205290-DB1725F9-4C40-4786-8891-D645291D65E1 Q35252752-9BA4595A-C485-4B35-B01E-54DD7EB86C0D Q35459288-278CA597-CC1D-48C8-BE18-7D47699ED54E Q35507680-29FB1763-168E-4620-8511-1AA0FA928908 Q35510507-6B11310F-A97D-4D03-B43B-144E728BD416 Q35519793-66009785-F1F4-4DF6-B273-1990473D92AF Q35558126-BA8E901F-6C99-42FD-AB5E-CEA5E4D63FBA Q35584239-0740A065-1122-4E2F-A7AB-A5ED7E5ADA25

P2860

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

http://www.wikidata.org/entity/Q34655437

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

The impact of new chemotherape ...... with metastatic breast cancer.

@ast

The impact of new chemotherape ...... with metastatic breast cancer.

@en

The impact of new chemotherape ...... with metastatic breast cancer.

@nl

type

label

The impact of new chemotherape ...... with metastatic breast cancer.

@ast

The impact of new chemotherape ...... with metastatic breast cancer.

@en

The impact of new chemotherape ...... with metastatic breast cancer.

@nl

prefLabel

The impact of new chemotherape ...... with metastatic breast cancer.

@ast

The impact of new chemotherape ...... with metastatic breast cancer.

@en

The impact of new chemotherape ...... with metastatic breast cancer.

@nl

P1433

Q34655437-D8E98131-57FF-4C90-AFD2-186A21C4C801

P1476

Q34655437-B6A7CDB1-AE3C-4DDC-9904-A1976938D4CC

P2093

Q34655437-0D6A7FD3-7581-4EA6-B8B9-AA33EF311E68

Q34655437-2CB394C8-6EA4-42C8-82A8-6E8EEE014B86

Q34655437-460B6F50-73F6-48E3-BA85-7A4802BDCE1E

Q34655437-47975211-C19A-4352-9C67-2C94B9E0124B

Q34655437-797672A7-9259-484B-A89A-3CE7B4E65671

Q34655437-9240E250-2226-4EE7-A0F1-5056C705E44A

Q34655437-ADDABB75-40AC-433A-98AA-66732CEBF1C9

Q34655437-BB770901-F29D-4C15-B99E-50CAF9A842FD

Q34655437-CB34B3F4-CA00-436F-A197-307976DC618A

Q34655437-E9868170-8A84-4462-B457-EBD19D1E0E29

P304

Q34655437-B9659B0F-C833-4705-B78D-C6F2F44A7591

P31

Q34655437-24235198-C781-47F5-A1B1-C21573822FF4

P356

Q34655437-11F18D59-0432-422A-970A-6EA622D2F362

P407

Q34655437-DCD0C2F8-B90E-4A4F-A51C-E7AE6841EFE8

P433

Q34655437-ACA422EE-7FCB-45C5-9426-8678BD73AAC8

P478

Q34655437-400619B1-73BA-4F86-8F91-14AD21C2A422

P577

Q34655437-08E3F908-B6C4-42BE-971B-3E4F5D6C4629

P5875

Q34655437-9A9ED6C9-C460-4E70-95F9-BA67E5518323

P698

Q34655437-8000D011-5648-4D48-A346-94A612F28861

P921

Q34655437-0F11DD9F-B58B-4D14-BC33-C019C56DB84A

P356

P1433

P1476

The impact of new chemotherape ...... with metastatic breast cancer.

@en

P2093

Andy Coldman

http://www.w3.org/2001/XMLSchema#string

Anna Kang

http://www.w3.org/2001/XMLSchema#string

Caroline H Speers

http://www.w3.org/2001/XMLSchema#string

Ivo A Olivotto

http://www.w3.org/2001/XMLSchema#string

Jeff Barnett

http://www.w3.org/2001/XMLSchema#string

Karen A Gelmon

http://www.w3.org/2001/XMLSchema#string

Stephen K Chia

http://www.w3.org/2001/XMLSchema#string

Susan E O'reilly

http://www.w3.org/2001/XMLSchema#string

Suzanne Malfair-Taylor

http://www.w3.org/2001/XMLSchema#string

Yulia D'yachkova

http://www.w3.org/2001/XMLSchema#string

P304

973-979

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22867

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6191903

http://www.w3.org/2001/XMLSchema#string

P698

17647245

http://www.w3.org/2001/XMLSchema#string

P921